Gregory T. Went
No más puestos en curso
Perfil
Gregory T.
Went is the founder who has founded CuraGen Corp.
in 1992, Tethys Bioscience, Inc. in 2002, and Adamas Pharmaceuticals LLC in 2000.
At CuraGen Corp., he held the title of Director & Executive Vice President in 1999.
At Tethys Bioscience, Inc., he held the title of Director from 2002 to 2009.
At Adamas Pharmaceuticals LLC, he held the titles of Chairman, President & Chief Executive Officer.
Dr. Went's former jobs include Chairman & Chief Executive Officer at Neuromolecular Pharmaceuticals, Inc., Director at ParAllele BioScience, Inc., Director at Angelica Therapeutics, Inc., Managing Director at Halteres Associates LLC, and Advisor at Presidio Partners.
Went received his undergraduate degree from Carnegie Mellon University in 1985 and his doctorate degree from the University of California, Berkeley in 1990.
Antiguos cargos conocidos de Gregory T. Went.
Empresas | Cargo | Fin |
---|---|---|
ADAMAS PHARMACEUTICALS, INC. | Chief Executive Officer | 11/09/2019 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Founder | 01/01/1999 |
ParAllele BioScience, Inc.
ParAllele BioScience, Inc. Miscellaneous Commercial ServicesCommercial Services ParAllele BioScience, Inc. provides genetic discovery solutions to the life science research, pharmaceutical and diagnostic sectors. The company's products and services utilize a multiplexed approach that leverages novel biochemical processes rather than complex instrumentation to discover and analyze minute variations in the human genome. The company was founded in October, 2001 and is located in San Francisco, CA. | Director/Board Member | - |
Neuromolecular Pharmaceuticals, Inc. | Chairman | - |
Halteres Associates LLC
Halteres Associates LLC Medical/Nursing ServicesHealth Services Halteres Associates LLC is a consulting firm founded in 2002 and based in an undisclosed location. The American company provides strategic and tactical consulting services to organizations in the areas of diagnostics, health, medical devices, and life science research. The private company leverage a robust network of industry professionals across multiple disciplines to assist organizations with technology creation and applications, product and market development, opportunity and economic analyses, business modeling, and more. The company's clients include large multinational companies, nongovernmental organizations, and emerging industry innovators. Halteres Associates is passionate about improving healthcare and can help create impact and value by matching medical innovation to market needs. | Corporate Officer/Principal | - |
Formación de Gregory T. Went.
Carnegie Mellon University | Undergraduate Degree |
University of California, Berkeley | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 8 |
---|---|
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
ParAllele BioScience, Inc.
ParAllele BioScience, Inc. Miscellaneous Commercial ServicesCommercial Services ParAllele BioScience, Inc. provides genetic discovery solutions to the life science research, pharmaceutical and diagnostic sectors. The company's products and services utilize a multiplexed approach that leverages novel biochemical processes rather than complex instrumentation to discover and analyze minute variations in the human genome. The company was founded in October, 2001 and is located in San Francisco, CA. | Commercial Services |
Neuromolecular Pharmaceuticals, Inc. | Health Technology |
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | Health Technology |
Adamas Pharmaceuticals LLC
Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Presidio Partners
Presidio Partners Investment ManagersFinance Presidio Partners is a venture capital firm founded in the year 1989 by Thomas R. Baruch. The firm is headquartered in San Francisco, California. | Finance |
Halteres Associates LLC
Halteres Associates LLC Medical/Nursing ServicesHealth Services Halteres Associates LLC is a consulting firm founded in 2002 and based in an undisclosed location. The American company provides strategic and tactical consulting services to organizations in the areas of diagnostics, health, medical devices, and life science research. The private company leverage a robust network of industry professionals across multiple disciplines to assist organizations with technology creation and applications, product and market development, opportunity and economic analyses, business modeling, and more. The company's clients include large multinational companies, nongovernmental organizations, and emerging industry innovators. Halteres Associates is passionate about improving healthcare and can help create impact and value by matching medical innovation to market needs. | Health Services |
Angelica Therapeutics, Inc. |
- Bolsa de valores
- Insiders
- Gregory T. Went